Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has demonstrated a strong positive outlook due to encouraging results from multiple clinical studies involving its flagship product, Ampligen (rintatolimod). Notably, the company reported positive data from a Phase 2 study assessing Ampligen for post-COVID conditions in February 2024, building on previous favorable results from an April 2022 Phase 2a study targeting metastatic colorectal cancer. The ongoing success in clinical trials highlights the potential for Ampligen to address significant unmet medical needs, which could drive future revenue growth and positively impact investor sentiment.

Bears say

AIM ImmunoTech Inc reported a net loss of $3.3 million, corresponding to an earnings per share (EPS) of $(1.57), which significantly exceeded analyst estimates of $(0.97) to $(0.98). The company's ongoing financial challenges are compounded by numerous risks, including liquidity concerns, the possibility of product candidates not proving safety and efficacy in clinical trials, and the failure to secure necessary regulatory approvals for commercialization. Additional factors such as competition, changing macroeconomic conditions, and fluctuating investor sentiment towards biotech stocks further contribute to a negative outlook for the company's stock performance.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.